Cargando…

Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses

BACKGROUND: Identifying new drug targets for inflammatory bowel disease (IBD) is urgently needed. The proteome is a major source of therapeutic targets. We conducted a proteome-wide Mendelian randomization (MR) and colocalization analyses to identify possible targets for IBD. METHODS: Summary-level...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jie, Xu, Fengzhe, Ruan, Xixian, Sun, Jing, Zhang, Yao, Zhang, Han, Zhao, Jianhui, Zheng, Jie, Larsson, Susanna C., Wang, Xiaoyan, Li, Xue, Yuan, Shuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986512/
https://www.ncbi.nlm.nih.gov/pubmed/36857861
http://dx.doi.org/10.1016/j.ebiom.2023.104494
_version_ 1784901184569475072
author Chen, Jie
Xu, Fengzhe
Ruan, Xixian
Sun, Jing
Zhang, Yao
Zhang, Han
Zhao, Jianhui
Zheng, Jie
Larsson, Susanna C.
Wang, Xiaoyan
Li, Xue
Yuan, Shuai
author_facet Chen, Jie
Xu, Fengzhe
Ruan, Xixian
Sun, Jing
Zhang, Yao
Zhang, Han
Zhao, Jianhui
Zheng, Jie
Larsson, Susanna C.
Wang, Xiaoyan
Li, Xue
Yuan, Shuai
author_sort Chen, Jie
collection PubMed
description BACKGROUND: Identifying new drug targets for inflammatory bowel disease (IBD) is urgently needed. The proteome is a major source of therapeutic targets. We conducted a proteome-wide Mendelian randomization (MR) and colocalization analyses to identify possible targets for IBD. METHODS: Summary-level data of 4907 circulating protein levels were extracted from a large-scale protein quantitative trait loci study including 35,559 individuals. Genetic associations with IBD and its subtypes were obtained from the Inflammatory Bowel Disease Genetics Consortium (25,024 cases and 34,915 controls), the FinnGen study (7206 cases and 253,199 controls), and the UK Biobank study (7045 cases and 449,282 controls). MR analysis was conducted to estimate the associations between protein and IBD risk. The colocalization analysis was used to examine whether the identified proteins and IBD shared casual variants. FINDINGS: Genetically predicted levels of 3, and 5 circulating proteins were associated with IBD and ulcerative colitis (UC), respectively. With high supporting evidence of colocalization, genetically predicted MST1 (macrophage stimulating 1) and HGFAC (hepatocyte growth factor activator) levels were inversely associated with IBD risks. The associations of STAT3 (signal transducer and activator of transcription 3), MST1, CXCL5 (C-X-C motif chemokine ligand 5), and ITPKA (inositol-trisphosphate 3-kinase A) with the risk of UC were supported by colocalization analysis. INTERPRETATION: The proteome-wide MR investigation identified many proteins associated with the risk of IBD. MST1, HGFAC, STAT3, ITPKA, and CXCL5 deserve further investigation as potential therapeutic targets for IBD. FUNDING: SCL is supported by research grants from the 10.13039/501100006636Swedish Research Council for Health, Working Life and Welfare (Forte; grant no. 2018-00123) and the 10.13039/501100004359Swedish Research Council (Vetenskapsrådet; grant no. 2019-00977). XYW is supported by research grants from the 10.13039/501100001809National Natural Science Foundation of China (81970494) and 10.13039/100016104Key Project of Research and Development Plan of Hunan Province (2019SK2041). XL is supported by research grants from the Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001).
format Online
Article
Text
id pubmed-9986512
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99865122023-03-07 Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses Chen, Jie Xu, Fengzhe Ruan, Xixian Sun, Jing Zhang, Yao Zhang, Han Zhao, Jianhui Zheng, Jie Larsson, Susanna C. Wang, Xiaoyan Li, Xue Yuan, Shuai eBioMedicine Articles BACKGROUND: Identifying new drug targets for inflammatory bowel disease (IBD) is urgently needed. The proteome is a major source of therapeutic targets. We conducted a proteome-wide Mendelian randomization (MR) and colocalization analyses to identify possible targets for IBD. METHODS: Summary-level data of 4907 circulating protein levels were extracted from a large-scale protein quantitative trait loci study including 35,559 individuals. Genetic associations with IBD and its subtypes were obtained from the Inflammatory Bowel Disease Genetics Consortium (25,024 cases and 34,915 controls), the FinnGen study (7206 cases and 253,199 controls), and the UK Biobank study (7045 cases and 449,282 controls). MR analysis was conducted to estimate the associations between protein and IBD risk. The colocalization analysis was used to examine whether the identified proteins and IBD shared casual variants. FINDINGS: Genetically predicted levels of 3, and 5 circulating proteins were associated with IBD and ulcerative colitis (UC), respectively. With high supporting evidence of colocalization, genetically predicted MST1 (macrophage stimulating 1) and HGFAC (hepatocyte growth factor activator) levels were inversely associated with IBD risks. The associations of STAT3 (signal transducer and activator of transcription 3), MST1, CXCL5 (C-X-C motif chemokine ligand 5), and ITPKA (inositol-trisphosphate 3-kinase A) with the risk of UC were supported by colocalization analysis. INTERPRETATION: The proteome-wide MR investigation identified many proteins associated with the risk of IBD. MST1, HGFAC, STAT3, ITPKA, and CXCL5 deserve further investigation as potential therapeutic targets for IBD. FUNDING: SCL is supported by research grants from the 10.13039/501100006636Swedish Research Council for Health, Working Life and Welfare (Forte; grant no. 2018-00123) and the 10.13039/501100004359Swedish Research Council (Vetenskapsrådet; grant no. 2019-00977). XYW is supported by research grants from the 10.13039/501100001809National Natural Science Foundation of China (81970494) and 10.13039/100016104Key Project of Research and Development Plan of Hunan Province (2019SK2041). XL is supported by research grants from the Natural Science Fund for Distinguished Young Scholars of Zhejiang Province (LR22H260001). Elsevier 2023-02-27 /pmc/articles/PMC9986512/ /pubmed/36857861 http://dx.doi.org/10.1016/j.ebiom.2023.104494 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Articles
Chen, Jie
Xu, Fengzhe
Ruan, Xixian
Sun, Jing
Zhang, Yao
Zhang, Han
Zhao, Jianhui
Zheng, Jie
Larsson, Susanna C.
Wang, Xiaoyan
Li, Xue
Yuan, Shuai
Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
title Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
title_full Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
title_fullStr Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
title_full_unstemmed Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
title_short Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
title_sort therapeutic targets for inflammatory bowel disease: proteome-wide mendelian randomization and colocalization analyses
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986512/
https://www.ncbi.nlm.nih.gov/pubmed/36857861
http://dx.doi.org/10.1016/j.ebiom.2023.104494
work_keys_str_mv AT chenjie therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalyses
AT xufengzhe therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalyses
AT ruanxixian therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalyses
AT sunjing therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalyses
AT zhangyao therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalyses
AT zhanghan therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalyses
AT zhaojianhui therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalyses
AT zhengjie therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalyses
AT larssonsusannac therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalyses
AT wangxiaoyan therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalyses
AT lixue therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalyses
AT yuanshuai therapeutictargetsforinflammatoryboweldiseaseproteomewidemendelianrandomizationandcolocalizationanalyses